Cyano-myracrylamide |
| カタログ番号GC90472 |
zDHHC20阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2801702-34-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cyano-myracrylamide (CMA) is an inhibitor of zinc finger DHHC domain-containing (zDHHC) palmitoyltransferase 20 (zDHHC20; IC50 = 1.35 µM in a cell-free assay).1 It selectively inhibits zDHHC20 over acyl-protein thioesterase 1 (APT-1) and APT-2 at 50 µM. CMA (5-20 µM) inhibits S-acylation of Legionella E3 ligase GobX, MyD88, and Ras, which are substrates of zDHHC20, zDHHC9, and zDHHC6, respectively, in HEK293T cells expressing recombinant Legionella GobX, recombinant human MyD88, or endogenous Ras. Unlike the zDHHC inhibitor 2-bromopalmitate (2BP), CMA is not toxic to HEK293T cells at 40 µM.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *